Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
1.470
-0.070 (-4.55%)
At close: May 17, 2024, 4:00 PM
1.480
+0.010 (0.68%)
After-hours: May 17, 2024, 5:51 PM EDT
Immuneering Stock Forecast
IMRX's stock price has decreased by -83.03% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Immuneering stock have an average target of 15.14, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 929.93% from the current stock price of 1.47.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immuneering stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 4 | 3 |
Buy | 1 | 1 | 1 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 9 | 10 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +920.41% | May 8, 2024 |
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +920.41% | Apr 12, 2024 |
Mizuho | Mizuho | Strong Buy Maintains $20 → $8 | Strong Buy | Maintains | $20 → $8 | +444.22% | Apr 2, 2024 |
Jefferies | Jefferies | Strong Buy → Hold Downgrades $16 → $3 | Strong Buy → Hold | Downgrades | $16 → $3 | +104.08% | Mar 15, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $21 → $16 | Strong Buy | Maintains | $21 → $16 | +988.44% | Mar 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.27M
EPS This Year
-1.98
from -1.88
EPS Next Year
-1.92
from -1.98
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 9.1M | n/a | 90.1M | 158.9M |
Avg | n/a | 1.3M | n/a | 25.6M | 50.8M |
Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 521.8% |
Avg | - | - | - | - | 98.7% |
Low | - | - | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.98 | -0.87 | -1.42 | -1.23 | -0.07 |
Avg | -1.98 | -1.92 | -2.12 | -1.70 | -1.38 |
Low | -2.33 | -2.57 | -2.84 | -2.43 | -2.80 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.